Peregrine Capital Management LLC Intercept Pharmaceuticals, Inc. Transaction History

Peregrine Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 30, 2020	SELL	$46.7 - $92.04 $4.09 Million - $8.05 Million	-87,500 Closed	0 $0
Q1 2020 Apr 17, 2020	BUY	$48.35 - $118.68 $1,547 - $3,797	32 Added 0.04%	87,500 $5.51 Million
Q4 2019 Jan 16, 2020	SELL	$57.36 - $124.1 $4.61 Million - $9.98 Million	-80,434 Reduced 47.91%	87,468 $10.8 Million
Q3 2019 Oct 16, 2019	BUY	$58.69 - $80.46 $2.26 Million - $3.1 Million	38,556 Added 29.81%	167,902 $11.1 Million
Q2 2019 Jul 18, 2019	BUY	$77.77 - $120.68 $1.34 Million - $2.08 Million	17,259 Added 15.4%	129,346 $0
Q1 2019 Apr 12, 2019	BUY	$91.83 - $120.68 $416,357 - $547,163	4,534 Added 4.22%	112,087 $0
Q4 2018 Jan 17, 2019	BUY	$85.79 - $126.46 $653,290 - $962,992	7,615 Added 7.62%	107,553 $10.8 Million
Q3 2018 Oct 18, 2018	SELL	$88.49 - $127.55 $4.56 Million - $6.57 Million	-51,496 Reduced 34.01%	99,938 $0
Q2 2018 Jul 12, 2018	BUY	$60.0 - $85.67 $2.17 Million - $3.1 Million	36,189 Added 31.4%	151,434 $0
Q1 2018 Apr 16, 2018	SELL	$52.72 - $67.25 $290,592 - $370,682	-5,512 Reduced 4.56%	115,245 $0
Q4 2017 Jan 24, 2018	BUY	$58.2 - $72.76 $7.03 Million - $8.79 Million	120,757	120,757 $0

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.